Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological malignancies. Ectopically expressed chimeric antigen receptors (CARs) reprogram immune cells to target and eliminate cancer. However, CAR T cell therapy's success depends on the balance between effective anti-tumor activity and minimizing harmful side effects. To improve CAR T cell therapy outcomes and mitigate associated toxicities, scientists from different fields are cooperating in developing next-generation products using the latest molecular cell biology and synthetic biology tools and technologies. The immunotherapy field is rapidly evolving, with new approaches and strategies being reported at a fast pace. This comprehensive literature review aims to provide an up-to-date overview of the latest developments in controlling CAR T cell activity for improved safety, efficacy, and flexibility.

• Klíčová slova
• CAR, Cancer, Cell therapy, Chimeric antigen receptor, Immunotherapy, Regulation, Synthetic, T cell,
• MeSH
• chimerické antigenní receptory * MeSH
• imunoterapie adoptivní škodlivé účinky   metody   MeSH
• imunoterapie MeSH
• lidé MeSH
• nádory * terapie   MeSH
• receptory antigenů T-buněk MeSH
• T-lymfocyty MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• chimerické antigenní receptory * MeSH
• receptory antigenů T-buněk MeSH